{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Beau-Faller M"],"funding":["French","National Cancer Institute","Ligue Nationale Contre le Cancer"],"pubmed_abstract":["<h4>Background</h4>There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations.<h4>Patients and methods</h4>EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network.<h4>Results</h4>Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], wor"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pagination":["126-31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3868323"],"repository":["biostudies-literature"],"pubmed_title":["Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network."],"pmcid":["PMC3868323"],"pubmed_authors":["Nanni-Metellus I","Lacroix L","Blons H","Lacave R","Escande F","Prim N","Bieche I","Rouquette I","Pretet JL","Voegeli AC","Baudrin L","Morin F","Besse B","Zalcman G","Solassol J","de Fraipont F","de Cremoux P","Cayre A","Lizard S","Tomasini P","Cadranel J","Beau-Faller M","Quoix E","Favre-Guillevin E","Legrain M","Ruppert AM","Wislez M"],"additional_accession":[]},"is_claimable":false,"name":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.","description":"<h4>Background</h4>There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations.<h4>Patients and methods</h4>EGFR exon 18 and/or exon 20 mutations were collected from 10 117 non-small-cell lung cancer (NSCLC) samples analysed at 15 French National Cancer Institute (INCa)-platforms of the ERMETIC-IFCT network.<h4>Results</h4>Between 2008 and 2011, 1047 (10%) samples were EGFR-mutated, 102 (10%) with rare mutations: 41 (4%) in exon 18, 49 (5%) in exon 20, and 12 (1%) with other EGFR mutations. Exon 20 mutations were related to never-smoker status, when compared with exon 18 mutations (P < 0.001). Median overall survival (OS) of metastatic disease was 21 months [95% confidence interval (CI) 12-24], wor","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Jan","modification":"2026-04-14T17:14:46.034Z","creation":"2025-07-28T03:04:09.49Z"},"accession":"S-EPMC3868323","cross_references":{"pubmed":["24285021"],"doi":["10.1093/annonc/mdt418"]}}